9 completed, 3 terminated, 3 withdrawn. 4 Phase 2, 3 Phase 1, 2 Early Phase 1, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 3 | Withdrawn 2, Completed 1 |
| Early Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 2 |
| Not applicable | 1 | Terminated 1 |
Follow Stage IIIC Primary Peritoneal Cancer: new trials by email Literature Review of Stage IIIC Primary Peritoneal Cancer trials Research Report on Stage IIIC Primary Peritoneal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Carboplatin, Quality-of-Life Assessment, Questionnaire Administration - Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer | Phase 2 | Completed | Wake Forest University Health Sciences | 50 | 2019-01-02 | 2026-08-21 |
| PET Imaging of Ovarian Carcinoma With 18F-FSPG (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG), Positron Emission Tomography, Laboratory Biomarker Analysis - Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer | Early Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2018-06-01 | 2018-06-06 | |
| Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, Recombinant NY-ESO-1 Protein, Sirolimus - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2017-12-08 | 2018-05-01 | |
| IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery Carboplatin, Gynecological Surgical Procedure, Laboratory Biomarker Analysis - Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer | Phase 2 | Terminated | University of Washington | 11 | 2017-04-03 | 2022-01-14 |
| Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent Aldesleukin, HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis - Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor | Phase 1 | Withdrawn | Barbara Ann Karmanos Cancer Institute | 2015-06-01 | 2016-02-17 | |
| Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor | Early Phase 1 | Completed | Mayo Clinic | 19 | 2014-04-14 | 2025-10-31 |
| Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine - Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma | Phase 1 | Completed | Mayo Clinic | 24 | 2012-07-24 | 2024-08-21 |
| Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer Adjuvant Therapy, Aprepitant, Carboplatin - Nausea and Vomiting, Ovarian Brenner Tumor | Not applicable | Terminated | Gynecologic Oncology Group | 4 | 2011-06-01 | 2018-05-22 |
| OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission Laboratory Biomarker Analysis, Polyvalent Antigen-KLH Conjugate Vaccine, Saponin-based Immunoadjuvant OBI-821 - Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer | Phase 2 | Completed | Gynecologic Oncology Group | 171 | 2010-07-01 | 2017-09-13 |
| Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Cognitive Assessment, Quality-of-Life Assessment - Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor | Completed | Gynecologic Oncology Group | 247 | 2010-04-01 | 2018-04-12 | |
| Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Carboplatin, Glutathione, Laboratory Biomarker Analysis - Chemotherapeutic Agent Toxicity, Neuropathy | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 195 | 2009-12-01 | 2017-02-23 |
| Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Bevacizumab, Temsirolimus - Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 252 | 2009-09-08 | 2019-01-25 |
| YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Terminated | Gynecologic Oncology Group | 2500 | 2007-09-01 | 2018-05-22 | |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1873 | 2005-09-01 | 2019-07-23 |
| Collecting Tumor Samples From Patients With Gynecological Tumors Laboratory Biomarker Analysis - Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor | Completed | Gynecologic Oncology Group | 275 | 1992-06-01 | 2016-10-28 |
Fallopian Tube Neoplasms (15) · Ovarian Neoplasms (15) · Brenner Tumor (5) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Dysgerminoma (1) · Gestational Trophoblastic Disease (1) · Melanoma (1) · Mesothelioma, Malignant (1) · Nausea (1) · Neurotoxicity Syndromes (1) · Ovarian Germ Cell Cancer (1) · Pain (1) · Sarcoma, Endometrial Stromal (1) · Somatostatinoma (1)
Adnexal Diseases (15) · Endocrine Gland Neoplasms (15) · Endocrine System Diseases (15) · Fallopian Tube Diseases (15) · Female Urogenital Diseases (15) · Female Urogenital Diseases and Pregnancy Complications (15) · Genital Diseases (15) · Genital Diseases, Female (15) · Genital Neoplasms, Female (15) · Gonadal Disorders (15) · Neoplasms (15) · Neoplasms by Site (15) · Ovarian Diseases (15) · Urogenital Diseases (15) · Urogenital Neoplasms (15)
Carboplatin (5) · Paclitaxel (3) · Taxes (3) · Bevacizumab (2) · Disulfides (2) · Immunoglobulin G (2) · Sirolimus (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 4-(3-fluoropropyl)glutamic acid (1) · Aprepitant (1) · Calcium Dobesilate (1) · Chemotherapy, Adjuvant (1) · Cisplatin (1) · Colony-Stimulating Factors (1) · Cyclophosphamide (1)
Gynecologic Oncology Group (5) · Mayo Clinic (2) · National Cancer Institute (NCI) (2) · Alliance for Clinical Trials in Oncology (1) · Barbara Ann Karmanos Cancer Institute (1) · Roswell Park Cancer Institute (1) · University of Washington (1) · Vanderbilt-Ingram Cancer Center (1) · Wake Forest University Health Sciences (1)
United States (13) · Canada (2) · Japan (1) · South Korea (1)
Matthew S. Block, M.D., Ph.D. (2) · Charles Loprinzi (1) · Henry Pitot (1) · John Liao (1) · Katherine Bell-McGuinn (1) · Kunle Odunsi (1) · Lawrence Lum (1) · Lisa Hess (1) · Marta Crispens, MD (1) · Michael Cibull (1) · Michael Kelly (1) · Paul Sabbatini (1) · Robert Burger (1) · Steven Plaxe (1)
PMID 21941283, PMID 22204724, PMID 23219660, PMID 25318437, PMID 25488966, PMID 26487588, PMID 29550184, PMID 31216226, PMID 31653510, PMID 35144591, PMID 36252167, PMID 37185961, PMID 37702588
U10CA180868 (4), U10CA027469 (3), U10CA101165 (2), N01CM00032 (1), N01CM00038 (1), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), N01CM62203 (1), N01CM62204 (1), N01CM62205 (1), N01CM62206 (1)